ERBB2 and gastric cancer: The KEYNOTE-811 trial demonstrated the efficacy of trastuzumab and pembrolizumab with chemotherapy in the treatment of HER2-positive gastric cancer [11], but this combination has not been tested against HER2-positive, MSI-H gastric cancer and has not been approved for use in Japan.